

## **PRALUENT**

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

PATIENT INFORMATION Date: Name: LID: Date of Birth:		_ Office Telephone:		
				Office Fax: Specialty: NPI#:
			TIAL CRITERIA QUESTIONS	1 1 (AGGVD)
		1.	Does the patient have a history of clinical ather If Yes, skip to #3 $\square$ Yes $\square$ $\square$ No	erosclerotic cardiovascular disease (ASCVD)?
2.	What is the diagnosis?  ☐ Primary hyperlipidemia including heterozygous familial hypercholesterolemia ☐ Homozygous familial hypercholesterolemia ☐ Other			
3.	What is the ICD-10 code?			
4.		mg/dL Unknown ACTION REQUIRED: Attach OL-C level. The LDL-C level must be dated within the six months		
5.	Is this request for continuation of therapy with	h a PCSK9 inhibitor?		
6.	Has the patient achieved or maintained an LDL-C reduction (e.g., LDL-C is now at goal, robust reduction in LDL C) as the result of a PCSK9 inhibitor therapy? $\square$ Yes $\square$ $\square$ No <i>No further questions</i>			
Prio	or Statin Therapy			
		dose daily, such as rosuva statin (Crestor) 20 mg daily or atorva statin , skip to $\#10$		
8.	Has the patient received this dose for at least 2	3 months? ☐ Yes ☐ No If No, skip to #10		
9.	Has the patient received the high-intensity statin dose for at least 3 months in combination with ezetimibe? ☐ Yes ☐ No Skip to diagnosis section			
10.	Was the patient unable to tolerate a high-inter ☐ Yes ☐ No If No, skip to #14	nsity statin due to adverse effects?		
11.	Is the patient receiving a moderate-intensity s  ☐ Yes ☐ No If No, skip to #14	tatin dose daily, such as atorvastatin (Lipitor) 20 mg or equivalent?		
12.	Has the patient received this dose for at least 2	3 months? ☐ Yes ☐ No If No, skip to #14		

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Praluent Enhanced SGM - 6/2022.

Prescriber or Authorized Signature		Date (mm/dd/yy)	
inf X	attest that this information is accurate and true, a formation is available for review if requested by (	11 0	
2.	Are there any secondary causes that could explain the	•	
<u>PR</u> 1.	RIMARY HYPERLIPIDEMIA  What is the patient's untreated (before any lipid-lowe chart notes indicating the untreated LDL-C level.	ring therapy) LDL-C level? <i>ACTION REQUIRED: Attach</i>	
<b>AT</b> 1.	experienced? ACTION REQUIRED: Attach chart in disease.  Acute coronary syndromes  Myocardial infarction  Stable or unstable angina  Coronary or other arterial revascularization proced artery bypass graft [CABG] surgery)  Stroke of presumed atherosclerotic origin  Transient ischemic attack (TIA)  Non-cardiac peripheral arterial disease of presume extremity PAD)	c cardiovascular disease (ASCVD) has the patient sotes confirming clinical atherosclerotic cardiovascular ure (e.g., percutaneous coronary intervention [PCI], coronary d atherosclerotic origin (e.g., carotid artery stenosis, lower y percent or greater stenosis on cardiac computed tomography	
16.	confirming the contraindication.	cations to statins? ACTION REQUIRED: Attach chart notes ent elevations in hepatic transaminase levels (e.g., alanine imes upper limit of normal)	
15.		e in creatine kinase (CK) level of greater than or equal to 10 is treatment with a statin? <i>ACTION REQUIRED: Attach diagnosis section.</i> $\square$ Yes $\square$ No	
	tolerance and Contraindications  Did the patient score a 7 or higher on the Statin-Associated REQUIRED: Attach chart notes confirming the SAL If Yes, skip to diagnosis section.   Yes No	ciated Muscle Symptom Clinical Index (SAMS-CI)? ACTION MS-CI score.	
13.	B. Has the patient received the high-intensity statin dose  ☐ Yes ☐ No Skip to diagnosis section	for at least 3 months in combination with ezetimibe?	

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Praluent Enhanced SGM - 6/2022.